Gaston Soria
Co-Founder & Scientific Chief & Officer OncoPrecision
Dr. Gaston Soria is Co-Founder and Chief Scientific Officer at OncoPrecision, where he coordinates the development of first-in-class ADCs and BsAbs by leveraging proprietary ex-vivo screening technologies based on patient-derived cells and healthy donors. Dr. Soria obtained his PhD in Cell Biology at the University of Buenos Aires, Argentina, with part of his training at the Erasmus Medical Center in the Netherlands. Later on, he performed a postdoctoral stay at the Institut Curie in France, extending his expertise on cancer biology, DNA replication and repair. In 2014 he started his own research Lab aiming to identify novel targets and synthetic lethal interactions with therapeutic potential for cancer treatment, collaborating with pharmaceutical companies such as Novartis and GSK.
Seminars
Diving into the critical bridge between chemical innovation and clinical success, this workshop addresses the identified gap in biological validation. Moving from in vitro chemistry too predictable in vivo performance requires chemists and biologists to collaboratively design ADCs with an optimized therapeutic index from the outset.
This is a must-attend for chemistry and protein engineering teams looking to ground their technical strategies in biological reality and improve translatability by:
- Correlating specific linker chemistries and conjugation sites with tumor microenvironment biology and patient-specific PK/PD data to build predictive models for how chemical modifications influence clearance rates, tumor exposure, and ultimately efficacy and safety margins
- Designing and interpreting relevant in vivo and ex vivo studies to validate novel linker or conjugation technologies, moving beyond simple stability assays to demonstrate a direct impact on widening the therapeutic window in resistant or sensitive tumor model
- Establishing a framework for early-stage decision-making that integrates analytical chemistry data, in vitro potency, and preliminary PK insights to select the most promising ADC candidate for further development, de-risking the path to the clinic
